Page last updated: 2024-09-03
elacridar and yqa14
elacridar has been researched along with yqa14 in 1 studies
Compound Research Comparison
| Studies (elacridar) | Trials (elacridar) | Recent Studies (post-2010) (elacridar) | Studies (yqa14) | Trials (yqa14) | Recent Studies (post-2010) (yqa14) |
|---|---|---|---|---|---|
| 284 | 8 | 119 | 10 | 0 | 10 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Li, J; Li, Z; Liu, F; Wang, X; Zhang, Z; Zhuang, X | 1 |
Other Studies
1 other study(ies) available for elacridar and yqa14
| Article | Year |
|---|---|
P-Glycoprotein (ABCB1) limits the brain distribution of YQA-14, a novel dopamine D3 receptor antagonist.
Topics: Acridines; Adenosine; Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazoles; Blood-Brain Barrier; Brain; Caco-2 Cells; Dibenzocycloheptenes; Diketopiperazines; Dopamine Antagonists; Half-Life; Heterocyclic Compounds, 4 or More Rings; Humans; Mice; Permeability; Piperazines; Quinolines; ROC Curve; Temperature; Tetrahydroisoquinolines | 2015 |